Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6Gynecologic 1

Conditions

Carcinoma, Renal Cell 23Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Lymphoma, Mantle-Cell 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × temsirolimus × Clear all
NCT01687673 2020-12-07

Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

University of California, San Francisco

Phase 2 Completed
29 enrolled 16 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01008917 2019-05-09

Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

University of California, San Francisco

Phase 1 Completed
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
252 enrolled 20 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

NCT01335074 2016-11-15

Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Philipps University Marburg

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT01079767 2014-03-04

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

Federation Francophone de Cancerologie Digestive

Phase 2 Terminated
6 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01567930 2012-12-17

Temsirolimus as Second-line Therapy in HCC

University of Tennessee Cancer Institute

Phase 2 Unknown
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡